| Clinical Study "Common" Name (formal title) | Number of enrollees | Funding source (pharmaceutical company/ National Institutes of Health [NIH]) | Year complete | Primary publication | Full study treatment protocol (if available) |
|---|---|---|---|---|---|
|
LUMINOUS (Observe the Effectiveness and Safety of Ranibizumab in Real- Life Setting [LUMINOUS]) |
Recruited: 30,138 Various studies evaluated different numbers of participants. This study evaluated patients who had previously been treated with intravitreal ranibizumab for neovascular AMD (n=16,167). |
Novartis (NCT01318941) |
2016 |
Holz FG, et al. and the LUMINOUS study group. Ranibizumab treatment patterns in prior ranibizumab-treated neovascular age-related macular degeneration patients: Real-world outcomes from the LUMINOUS study. PLoS One. 2020;15(12):e0244183. https://pubmed.ncbi.nlm.nih.gov/33378369/ |
N/A LUMINOUS, a 5-year, prospective, multicenter, observational study, recruited 30,138 adult patients (treatment-nave or prior ranibizumab-treated or other ocular treatments) across all approved indications for ranibizumab. Treatment was per local ranibizumab labeling. [Holz.PLoSOne.2020] |